In three new studies that could redefine how cancer is viewed, researched, and treated, scientists have created a detailed map of the genetic mutations that underlie two of the deadliest forms of the disease: pancreatic cancer and glioblastoma, the type of brain tumor that Senator Edward Kennedy was diagnosed with this past spring. The new findings are the first steps in the huge task of mapping the genomes of cancer, as researchers work to learn about cancers from the ground up.

Scientists have known for decades that cancer develops in response to genetic changes that cause cells to grow and divide uncontrollably. But uncovering each of these changes, and understanding how they lead to disease, is a Herculean task–one that involves sequencing and analyzing upward of 100 different kind of tumors, with hundreds of different patient samples of each. And while some believe that systematically cataloging the mutations could provide unprecedented insight into fighting or even preventing cancers, others believe that the high cost of such research might not be worth the rewards. These papers provide the first glimpse at what the rewards could be.

One paper, published online in Nature, is the first study born from data gathered by the publicly funded Cancer Genome Atlas (TCGA), an initiative created to use large-scale genome sequencing to find and map different cancers’ genetic aberrations. Lynda Chin and Matthew Meyerson, both at the Dana-Farber Cancer Institute, in Boston, analyzed more than 200 glioblastoma tumors for genetic changes (such as the number of copies of each protein-coding gene present in the sample, and whether these genes have been turned off through a process called methylation), and they also analyzed 600 genes already implicated in the disease. Their results confirmed known culprits and revealed previously unknown changes in three major genes: two known tumor suppressors (NF1 and ERBB2), and one that is newly associated with cancer (PIK3R1) and could potentially be targeted by drugs already in development.

The other two studies–the fruits of a private cancer genome project headed by a trio of researchers at Johns Hopkins University, in Baltimore–analyzed far fewer tumors at a far greater level of detail. Published online in Science, these papers examine 22 pancreatic tumors and 24 glioblastomas for gene copy number and gene expression, as well as the sequences of just about every single one of their more than 20,000 protein-encoding genes. The researchers found an average of around 60 genetic changes per tumor, but they also discovered that most of those mutations acted on a core set of just 12 cellular pathways.

These pathways may be central to future drug development. “It may be more productive to screen for drugs that act against the core pathways,” says Bert Vogelstein, one of the project heads at Johns Hopkins. “By targeting the pathways, it’s possible that new drugs could be effective against a much greater fraction of tumors.”

One finding in particular by the Johns Hopkins group shows the value of the genome-wide approach. Victor Velculescu, who led the Hopkins glioblastoma study, and his colleagues discovered that a mutation in one gene differentiates one subset of glioblastomas from another in a disease that researchers had always believed was quite homogeneous. The gene, called IDH1, had never before been implicated in any cancer. But the IDH1 mutation occurred in 12 percent of glioblastoma patients, and those people were, on average, 20 years younger and survived significantly longer than patients without the mutation. This finding–perhaps the most instantly clinically relevant piece of the three studies released today–is one that the scientists hope could soon be used to help physicians better predict their patients’ survival. The finding could also help clinicians determine if existing therapies might be more effective on this brand of glioblastoma and ultimately help create treatments directed specifically at the IDH1 pathway.

Cancer researchers welcome the flood of data gleaned from both approaches. “I’m just glad the information is in the till,” says Paul Mischel, a neuropathologist at the University of California, Los Angeles, who specializes in glioblastoma therapy development and application. “These studies provide the first really well-delineated set of road maps.” Chin and Velculescu hope that sequencing costs will soon drop low enough to allow them to combine the two techniques, sequencing large numbers of genes in many tumors.

The studies have also revealed to scientists looking to treat these diseases just how difficult their challenge really is. “For the first time, these are giving you the complete picture of these two cancer types,” Velculescu says. “This is important, because if we ever want to cure cancer, we have to know what’s wrong with it. And unfortunately, what appears to be wrong with most cancers is more complicated than we may have anticipated.”